iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
MONTREAL, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Ropack Inc., provider of contract manufacturing and packaging services for the pharmaceutical and nutraceutical industries, announced the purchase of two pharmaceutical facilities in Long Island, New York. The acquisition significantly expands the company’s capabilities which will now include research and development, formulation, lab analysis and commercial and clinical manufacturing, complementing its well-established solid oral dosage packaging and clinical study distribution.
The buildings, formerly operated by Forest Laboratories, LLC, total 213,700 square feet and are a realization of Ropack Inc.’s strategic expansion plan. “It has been a longstanding goal to broaden our service offerings,” noted Yves Massicotte, President and CEO. “To establish a presence in the United States at the same time makes this acquisition ideal.” Activities in the US territory will be managed through Ropack USA Inc. Mr. Massicotte added that Ropack Inc. and Ropack USA Inc. will now be known as “Ropack Pharma Solutions.”
“The purchase of these two state-of-the-art pharmaceutical facilities on Long Island will enable Ropack Pharma Solutions to provide its current and future customers with comprehensive solid oral dosage development, manufacturing and packaging solutions,” remarked Paul Dupont, Vice President of Marketing and Business Development. “This acquisition will add considerable capacity and key technologies to support projects from formulation development through commercialization.”
Ropack Inc., celebrating its 40th anniversary in 2016, operates four facilities in Montreal, Canada, for the packaging of solid oral dosage in bottles, flip-top vials, blister packs, stick-packs and sachets. It also is a leading Canadian clinical trial depot. It counts among its current customers many of the largest and most-respected companies in the pharmaceutical and nutraceutical industries.
Contact: Paul Dupont, VP Marketing and Business Development Ropack Pharma Solutions (514) 353-7000 [email protected] [email protected]
